Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Quest Diagnostics announces net income of $342 million for third quarter of 2015

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, announced today that for the quarter ended September 30, 2015, adjusted net income was $172 million compared to $161 million for 2014. Adjusted diluted EPS excluding amortization was $1.28 in the third quarter of 2015, compared to $1.20 in 2014.

From Quest Diagnostics 22 Oct 2015

Scientists find new way to inhibit growth of lung cancer cells

Scientists have identified a new way to stop the growth of lung cancer cells, by blocking their ability to use alternative sources of nutrition. The discovery was made possible by identifying the metabolic programs used by cancer cells to fuel their growth.

21 Oct 2015

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer.

19 Oct 2015

Rare genetic mutation could improve outcomes in NSCLC patients with brain metastases

Most patients with non-small cell lung cancer (NSCLC) that has metastasized to the brain have a dire prognosis. But Yale researchers have identified a subset of those patients with a rare genetic mutation who are living significantly longer than patients without the mutation.

16 Oct 2015

EKF’s PointMan™ used in cancer biopsy research

EKF, announces results from a study involving EKF Molecular’s PointMan™ DNA enrichment technology have been published in Clinical Cancer Research.

From EKF Diagnostics 15 Oct 2015

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

A University of Colorado Cancer Center study recently published online ahead of print in the journal Oncotarget reports "robust antitumor activity" of the drug TAK-733 in cells and mouse models of colorectal cancer.

14 Oct 2015

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it now provides clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx immunohistochemistry test, available through Dako, an Agilent Technologies company.

From Quest Diagnostics 13 Oct 2015

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

11 Oct 2015

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) says the move by the U.S. Food and Drug Administration (FDA) to grant accelerated approval for a cutting-edge lung cancer treatment is a positive step forward that may help many patients improve their survival.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

OncoGenex Pharmaceuticals, Inc. announced today that the European Medicines Agency has completed its review of the proposed amendment to the company's Phase 3 AFFINITY protocol and statistical analysis plan.

8 Oct 2015

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer.

8 Oct 2015

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

Boehringer Ingelheim announced today results of a new European survey investigating therapy goals, prescribing habits and decision-making criteria of physicians treating patients with advanced lung cancer with adenocarcinoma histology after first-line chemotherapy.

29 Sep 2015

Small Cell Lung Cancer News and Research

Quest Diagnostics announces net income of $342 million for third quarter of 2015

Scientists find new way to inhibit growth of lung cancer cells

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

Rare genetic mutation could improve outcomes in NSCLC patients with brain metastases

EKF’s PointMan™ used in cancer biopsy research

CU Cancer Center study reports 'robust antitumor activity' of TAK-733 drug in mouse models of colorectal cancer

Quest Diagnostics provides Dako’s PD-L1 complementary diagnostic test for non-squamous non-small cell carcinoma

FDA approves Opdivo to treat patients with advanced non-small cell lung cancer

IASLC commends pembrolizumab drug approval for cutting-edge lung cancer treatment

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

EMA completes review of proposed amendment to OncoGenex's Phase 3 AFFINITY trial protocol

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News